Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Investigations

  • 79 clinical trials
  • 29 recruiting
  • 93 conditions
  • 21 countries

Conditions in this area

93 conditions with trials, the busiest first

Drug level12Human epidermal growth factor receptor negative8Fallopian tube cancer6Peritoneal cancer index6Breast cancer5Hormone receptor positive breast cancer5Allergy test4Allergy test positive3BRAF V600E mutation positive3Breast cancer female3Breast cancer metastatic3Hormone receptor positive HER2 negative breast cancer3Magnetic resonance imaging3Ovarian cancer recurrent3Colonoscopy2Cortisol abnormal2Hepatitis B e antigen negative2Hepatitis B virus test2Hypersensitivity2Infertility2Infertility female2Infertility tests normal2Non-small cell lung cancer stage IV2Ovarian cancer2+69

Clinical trials in Investigations

79 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

79 clinical trials

Allergy test positive

Recruiting

Sensitivity and specificity of Lepidoglyphus destructor extract, sodium chloride and histamine dihydrochloride in skin prick test for Lepidoglyphus destructor allergy patients

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Inmunotek S.L.

Breast cancer+4

Recruiting

Study of elacestrant and ribociclib compared to standard treatment for patients with high-risk ER+/HER2- early breast cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Elacestrant
  • Sponsor:WSG Women's Cancer Study Group GmbH

Endometrial cancer+3

Recruiting

Study of ubamatamab alone or with cemiplimab for adults with ovarian, fallopian tube, peritoneal, or endometrial cancer that has come back

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Breast cancer+3

Recruiting

A Study Comparing GDC-4198 Alone and with Giredestrant versus Abemaciclib with Giredestrant for Advanced Breast Cancer After Previous CDK4/6 Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Genentech Inc.

Transplant rejection+1

Recruiting

A Study of Belimumab to Help Identify Safe Kidney Transplant Matches in Patients with High Antibody Levels Against Donor Tissue Types

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Belimumab
  • Sponsor:Leids Universitair Medisch Centrum (LUMC)

Hypersensitivity+1

Recruiting

A Study Testing Prolonged versus Single Dose Penicillin Challenge in Patients with Suspected Penicillin Allergy Using Amoxicillin

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Amoxicillin Trihydrate
  • Sponsor:Austin Health

Antibiotic level therapeutic

Recruiting

Study of antibiotic treatment effectiveness in critically ill patients receiving drug combination therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Amikacin Sulfate
  • Sponsor:Centre Hospitalier Universitaire De Nimes

Adenocarcinoma pancreas+1

Recruiting

Study of drug combination therapy after surgery in patients with resectable pancreatic ductal adenocarcinoma using lab-grown mini-tumors to guide treatment selection

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Universitaetsklinikum Ulm AöR

Colorectal cancer metastatic+1

Recruiting

Study of encorafenib and cetuximab treatment for patients with BRAF V600E-mutant metastatic colorectal cancer who previously responded to BRAF inhibitor therapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Encorafenib
  • Sponsor:Vall D Hebron Institute Of Oncology

Gastrooesophageal cancer+2

Recruiting

Study of Simvastatin with Nivolumab and Oxaliplatin for Patients with Advanced Stomach or Esophageal Cancer with ARID1A Mutation

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale

Triple negative breast cancer+2

Recruiting

Study of Patritumab Deruxtecan and Pembrolizumab for Patients with High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive Breast Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Merck Sharp & Dohme LLC

Ejection fraction normal+1

Recruiting

Study on Preventing Atrial Fibrillation After Heart Surgery Using Landiolol Hydrochloride in Patients with Normal Heart Function

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Landiolol Hydrochloride
  • Sponsor:Medical University Of Vienna

Substances studied in this area

The therapies tested most often in Investigations trials.

Sodium Chloride11 clinical trialsPaclitaxel6 clinical trialsHistamine Dihydrochloride5 clinical trialsPembrolizumab4 clinical trialsAbemaciclib3 clinical trialsCapecitabine3 clinical trialsCarboplatin3 clinical trialsDoxorubicin Hydrochloride3 clinical trialsGadobutrol3 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.